Boston Scientific shares drop 5.9% at the open

Boston Scientific Corporation (BSX) shares opened 5.9% lower on August 26, 2026, continuing a downward trend that has persisted since the company issued a revised growth outlook earlier in the year. Analysts have cited concerns over slower growth in key segments, including U.S. electrophysiology and the Watchman device, as primary factors behind the decline. Several major firms, including Raymond James and Goldman Sachs, have downgraded their ratings, reflecting a more cautious outlook on the company’s near-term performance.

The company’s 2026 growth forecast has also raised eyebrows among investors, as it appears to fall below consensus expectations for critical profit metrics. Management has acknowledged that recent portfolio changes may temporarily impact reported growth. These concerns are compounded by ongoing legal challenges, including a securities class-action lawsuit alleging misleading disclosures about revenue outlooks and competitive pressures in the U.S. Electrophysiology market.

Despite positive clinical trial results for the Watchman FLX device and the EKOS system, the market has remained skeptical, with investors focusing on mixed data and high expectations. The stock’s decline reflects a broader reassessment of Boston Scientific’s growth trajectory amid evolving market dynamics and regulatory scrutiny.